Category Archives: Uterus

Gynecological, Uterus

FIGO Grading

The International Federation of Gynecology and Obstetrics (FIGO) grading system for endometrial endometrioid carcinoma:

  • FIGO Grade 1:  <=5% solid, non-glandular, non-squamous growth
  • FIGO Grade 2:  6-50% solid, non-glandular, non-squamous growth
  • FIGO Grade 3:  >50% solid, non-glandular, non-squamous growth

Marked cytologic atypia increases the grade by 1.

FIGO Grading is only performed on endometrioid and mucinous adenocarinomas.  Other tumor subtypes (clear cell, serous, carcinomasarcomas) carry their own associated grade.  Mucinous adenocarcinomas are considered to be closely related to endometrioid carcinomas.

References

  1. Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019;38 Suppl 1: S64–S74. doi:10.1097/PGP.0000000000000518
Organ Systems, Gynecological, Cervix, Uterus, IHC Panels

Endometrial vs. Endocervical Adenocarcinoma

Endocervical vs. Endometrial Adenocarcinoma
Endocervical and endometrial adenocarcinomas may be morphologically indistinguishable morphologically.  The question often comes up as to whether a case represents an endometrial adenocarcinoma involving the cervix, or and endocervical adenocarcinoma involving the endometrium.  The following antibodies may be helpful in such circumstances:
 
 
Endocervical
Adenocarcinoma
Endometrial
Adenocarcinoma
Negative (7-8%+)
Positive (70-93%)
Positive (65-95%)
Usually Negative
Negative (4-20%+, 38% weak)
Strong Positive (67-90%)
Strong & Diffuse Positive (90-100%)
Patchy Positive cells (~35%)
HPV
Positive (67%)
Negative
References
AJSP 2002;26:998
 
“Endocervical vs. Endometrial Adenocarcinoma:  Update on Useful Immunohistochemical Markers.”  RT Miller,The Focus ProPath Immunohistochemistry.”   April 2003.
Organ Systems, Gynecological, Uterus

Endometrial Adenocarcinoma

Endocervical vs. Endometrial Adenocarcinoma
Endocervical and endometrial adenocarcinomas may be morphologically indistinguishable morphologically.  The question often comes up as to whether a case represents an endometrial adenocarcinoma involving the cervix, or and endocervical adenocarcinoma involving the endometrium.  The following antibodies may be helpful in such circumstances:
 
 
Endocervical
Adenocarcinoma
Endometrial
Adenocarcinoma
Negative (7-8%+)
Positive (70-93%)
Positive (65-95%)
Usually Negative
Negative (4-20%+, 38% weak)
Strong Positive (67-90%)
Strong & Diffuse Positive (90-100%)
Patchy Positive cells (~35%)
HPV
Positive (67%)
Negative
References
AJSP 2002;26:998
 
“Endocervical vs. Endometrial Adenocarcinoma:  Update on Useful Immunohistochemical Markers.”  RT Miller,The Focus ProPath Immunohistochemistry.”   April 2003.